Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.75 USD | +4.87% |
|
+7.14% | -28.57% |
26/06 | Transcript : Quince Therapeutics, Inc. - Special Call | |
25/06 | Quince Therapeutics Doses First Patient in Phase 3 Trial of EryDex to Treat Ataxia-Telangiectasia | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.57% | 3.24Cr | |
+19.41% | 4.55TCr | |
-8.62% | 3.85TCr | |
+38.65% | 3.81TCr | |
+26.95% | 3.07TCr | |
-13.50% | 2.6TCr | |
+10.74% | 2.59TCr | |
+44.87% | 1.41TCr | |
+34.36% | 1.27TCr | |
-7.14% | 1.13TCr |
- Stock Market
- Equities
- QNCX Stock
- News Quince Therapeutics, Inc.
- Quince Therapeutics Doses First Patient in Phase 3 Trial of EryDex to Treat Ataxia-Telangiectasia